PCSK9 and chronic kidney disease: Emerging PCSK9 inhibitors exhibit consistent LDL-C lowering across CKD stages in FOURIER/ODYSSEY trials [43,44], yet their exclusion of severe CKD and dialysis patients precludes definitive safety/efficacy conclusions in advanced CKD.